“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
Mytesi’s sales and gross sales at the time of the 2020 quarter were approximately $3.2 million and approximately $6.3 million, respectively, at the time of the 2020 quarter.
Reminder: The company will make a call to investors on Thursday, August 13 at 8:30 a.m. East Time, to receive monetary information and trade updates for the second quarter of 2020
Book the date: October 20, 2020, October 20, 2020, the company will host a virtual school occasion on diarrhoea dialogues for investors and business development contacts, which will focus on cancer-related diarrhoea
SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2020 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) published its consolidated monetary effects by the time of the 2020 quarter.
Monetary effects of the company for the time quarter of 2020:
Net sales of Mytesi products: Net sales at the time of the 2020 quarter were approximately $3.2 million and $1.7 million at the time of the 2019 quarter. This second quarter 2020 result represented 186% of the same was in 2019, an accumulation of $1.5 million in the quarter. Fixed Net sales in the first quarter of 2020 were approximately $830,000. Net sales by the time of the 2020 quarter accounted for 378% in the first quarter of 2020, an increase of $2.3 million quarter-by-quarter.
Mytesi Gross Revenue (non-GAAP): Gross sales at the time of the 2020 quarter were approximately $6.3 million and $2.4 million at the time of the 2019 quarter. The result of this time of the 2020 quarter represented 268% of the same was in 2019, an accumulation of $3.9 million quarter by quarter. Gross sales in the first quarter of 2020 were approximately $1.3 million. Gross sales at the time of the 2020 quarter accounted for 482% in the first quarter of 2020, an increase of approximately $5.0 million quarter-by-quarter. Neonorm’s gross sales were significant for all eras.
Total Mytesi bottles sold: The total Mytesi bottles sold by the time of the 2020 quarter accounted for 104.3% of the bottles sold for the same in 2019. The total mytesi bottles sold at the time of the 2020 quarter accounted for 155% of the bottles sold for the first quarter of 2020.
It ended three months
Highlights
June 30
(thousands, consistent with consistent percentage amounts)
2020
2019
$ change
% change
Net source of profit from profits
Ps
3 167
Ps
1 706
Ps
1 461
85,6
%
Operational loss
Ps
(8 451
)
Ps
(10 622
)
Ps
2 171
-20,4
%
Net loss
Ps
(9 238
)
Ps
(16 721
)
Ps
7 483
-44,8
%
Net loss attributable to regular shareholders
Ps
(10 597
)
Ps
(16 721
)
Ps
6 124
-36,6
%
Net loss consistent with stock, fundamental and diluted
Ps
(0,44
)
Ps
(15,11
)
Ps
14,67
-97,1
%
Operating expenses: Total operating expenses for the time of the 2020 quarter were $11.6 million, compared to $12.3 million last year, a low of 6% or $0.7 million year after year. Minimization in overhead due to a impairment rate of $4.0 million at the time of the 2019 quarter and none in the same quarter was this year, a minimisation of approximately $1.0 million in product, study and development, and compensation sales and marketing expenses. $3.7 million in collateral incentive rate and an accrual in general and administrative expenses of $0.6 million.
Cost of earnings: Total earnings prices for the quarters ended June 30, 2020 and June 30, 2019 were $1.0 million (33% of earnings) and $1.3 million (74% of profits), respectively, 18% or 0.2 million, a minimized quarter. more than a quarter. The minimization in the charge of product sales was due to a unique cancellation of stock and maintenance of non-complianm appliances during the 3 months ended June 30, 2019.
Research and Development: Research and progression expenses were $1.4 million by the time of the 2020 quarter, to $1.7 million by the time of the 2019 quarter, a low of 17%, or $0.3 million, quarter by quarter. A minimum of approximately $0.6 million in contract production prices for innovations in production procedures is offset by an accumulation of $0.3 million in consulting, formulas and regulatory pricing.
Sales and marketing: Sales and marketing expenses were $1.7 million by the time of the 2020 quarter, compared to $2.2 million by the time of the 2019 quarter, a low of 20%, or $0.4 million, quarter after quarter. Minimizing sales and marketing expenses due to $0.6 million relief in sales force was offset by an accumulation of $0.2 million in direct marketing, consulting and stock-based compensation.
General and Administrative: General and administrative expenses were $3.8 million by the time of the 2020 quarter, compared to $3.2 million by the time of the 2019 quarter, an increase of 17.5%, or $0.6 million, year after year. The increase in overhead and administrative expenses due to an increase in accounting, legal and share-based reimbursement of $0.6 million, offset by a minimisation in consulting, travel, IT and third-party services prices of $0.5 million.
Intangible asset depreciation: A $4.0 million impairment rate related to our indefinite intangible assets recorded in the quarter ended June 20, 2019 and not in the quarter ended June 30, 2020.
Series 3-like incentive rates: In May 2020, the value of Series 1, 2, and Relay guarantees was reduced to $0.49 based on the percentage consistent with an incentive to be offered from Series 3 guarantees that can simply be corrected as a consistent, non-unusual percentage in an unacted training. holders of vouchers who promptly trained. Series 3 warrants were rated and charged as consistent with expenses of approximately $3.7 million.
Operating loss: At the time quarter of 2020, operating loss of $8.5 million, compared to a loss of $10.6 million at the time of the 2019 quarter, a low of 20% or $2.1 million quarter by quarter. The accumulation in the value of the Mytesi list resulted in a minimisation in our operating loss and a minimisation of overall operating expenses of 6% or $0.7 million compared to the quarter ended June 30, 2019.
Net loss: Net loss at the time of the 2020 quarter of $9.2 million, compared to a net loss of $16.7 million at the time of the 2019 quarter, a low of 45%, or approximately $7.5 million quarter-by-quarter. Minimizing net loss due to an accumulation in Mytesi’s list price, minimizing the operating loss of $2.2 million and minimizing interest expenses of $3.2 million. A $2.7 million loss on debt relief recorded in the quarter ended June 30, 2019 and none at the same time this year.
Net loss attributable to non-unusual shareholders: Net loss attributable to non-unusual shareholders by the time of the 2020 quarter $10.6 million compared to $16.7 million by the time of the 2019 quarter. An estimated dividend of $1.4 million related to the Company’s convertible shares and warrants. registered in the 3 months ended June 30, 2020.
Non-GAAP EBITDA: Non-GAAP EBITDA for the 2020 quarter and quarter 2019, a net loss of $7.6 million and $12.2 million, respectively. Excluding debt termination loss and other non-GAAP recurring expenses, non-GAAP recurring EBITDA represented a loss of approximately $3.9 million and $5.5 million for the 2020 quarter and the 2019 quarter, respectively.
It ended three months
June 30
2020
2019
(unaudited)
Net loss (thousands):
Ps
(9 238
)
Ps
(16 721
)
Settings:
Interest costs
479
3 657
Amortization and equipment
11
15
Amortization of intangible assets
422
422
Stock reimbursement expenses
749
446
Income taxes
–
–
Non-GAAP EBITDA
Ps
(7 577
)
Ps
(12 181
)
Depreciation of intangibles with indefinite useful life
–
4000
Debt sunset
–
2 663
Warr-Finance Amendment and Extinction
3 696
–
Non-GAAP EBITDA
Ps
(3.881
)
Ps
(5 518
)
Note related to the use of non-GAGA measures
The Company completes its abstract consolidated monetary statements on a GAAP basis by offering gross sales, non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. Jaguar believes that data from these non-PCGA measures provide investors with more data that reflects the basis on which the Company’s control evaluates and operates the business. These non-GAGA monetary measures do not comply with GAGA and should not be considered in isolation or as substitutes for PCGA net sales and GAAP net loss and are neither substitutes nor impressive to the monetary functionality measures that GAAP complies with.
Gross sales percentages are based on gross sales figures that constitute Mytesi wholesale orders in Jaguar’s third-party logistics warehouse, which generate sales and flow of billed money to Napo Pharmaceuticals, Inc. (“Napo”), Jaguar’s wholly owned subsidiary. Gross sales are used internally through control as an indicator and to monitor operational pershapeance, adding Mytesi sales pershapeance, sales pershapeance, and expansion or profit reduction. The Company believes that the presentation of gross sales provides a useful measure closer to the real time of our operational evolution. Gross sales are not a measure that is recorded in accordance with the accounting principles sometimes accepted in the United States of America (“GAAP”) and do not deserve to be considered as an option for net sales, which are decided in accordance with GAAP. , and deserve not to be used on their own as an indicator of operational profitability rather than profits. In addition, gross sales would possibly not be comparable to the securities measures used through other companies, as gross sales have been explained through the Company’s internal reporting practices. In addition, gross sales would possibly not be made in the form of money flow, as promotional invoices and bonuses would possibly be deducted from invoices earned from certain customers. Mytesi’s gross sales are reduced through Medicare, ADAP 340B debit releases, returns, and wholesale prices based on old trends to calculate net sales.
The Company defines non-GAAP EBITDA as the net loss before interest and other expenses, property, plant and equipment, amortization of intangible assets, inventory reimbursement expense, and provision or source of tax revenue. The Company defines non-GAAP recurring EBITDA as non-GAAP adjusted EBITDA for certain non-recurring income and expenses. The Company’s control believes that non-GAAP EBITDA and non-GAAP recurring EBITDA are significant signs of Jaguar’s functionality and provide useful data to investors related to the effects of the Company’s operations and monetary position.
Instructions for the convention call When: Thursday, August 13 at 8:30 am Eastern Call (toll-free number in the U.S.): 800-289-0438 Call (international): 323-794-2423 Conference IDENTIFICATION Number: 1021156 Live web broadcast on Jaguar Segment Investor Relations (click here)
Composite Playback Instructions (Us Free Edition): 844-512-2921 Call Number (International): 412-317-6671 Reading Pine Number: 1021156 Re-editing the webcast on Jaguar’s Investor Relations Segment (click here)
BOOK THIS DATE:
Virtual dialogues on the diarrhoea disease education event scheduled for October 20, 2020
Jaguar plans to hold a virtual “Diarrhea Dialogues” disease education event for investors and business progress contacts on Tuesday, October 20, 2020. Leading oncologists, patient advocates, and care experts will discuss the importance of direct care for others with chronic diseases. suffering of the decreased gastrointestinal tract, i.e. with respect to debilitating diarrhea resulting from cancer treatment. Jaguar will publish more key points on the occasion, as well as data on how investors and trading progression contacts can signal to participate as the October deadline approaches.
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercially-stage pharmaceutical company aimed at the progression of new herbal, non-opioid and sustainable prescription drugs for other people and animals with gastrointestinal problems, namely chronic and debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on the progression and marketing of exclusive human gastrointestinal prescription drugs based on responsibly collected plant plants in tropical forest areas. Our mytesi® (crofelemer) product is approved by the U.S. FDA. For symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS receiving antiretroviral treatment and the only FDA-approved botanical herbal drug guidance.
For more information about Jaguar, https://jaguar.health. For more information about Napo, www.napopharma.com.
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal drug indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS in antiretroviral processing (ART). Mytesi is not indicated for the remedy of infectious diarrhea. Remove infectious etiologies from diarrhea before starting Mytesi. If infectious etiologies are not taken into account, there is a threat that patients with infectious etiologies will not obtain the right remedy and their disease may worsen. In clinical studies, the maximum non-unusual side effects that occurred at a rate higher than placebo were upper respiratory tract infections (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%) and the accumulation of bilirubin. (3,1%). ).
See Mytesi.com for full prescription details. Crofelemer, the active element of Mytesi, is a botanical medicine (plant-based) extracted and purified from the sap of the red bark of the medicinal tree Croton lechleri in the Amazon rainforest. Napo has implemented a sustainable crofelemer harvesting program with a high degree of quality and ecological integrity.
Forward-looking statements
Certain statements contained in this press release constitute “forward-looking statements”. These come with statements regarding the confidence that Jaguar will make an appeal for investors on Thursday, August 13, 2020 at 8:30 a.m. EASTERN time, and the expectation that the company will host a virtual disease education event “Dialogue Diarrheas” on Tuesday. October 20, 2020. In some cases, you may identify forward-looking statements through words such as “possibly,” “will,” “should,” “expect,” “plan,” “objective,” “anticipate,” “could,” “intend,” “objective,” “project,” “consider,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of those or other similar terms. The forward-looking statements in this press release are only predictions. Jaguar founded these forward-looking statements largely on its existing expectations and projections related to long-term occasions. These forward-looking statements relate only to the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and others are beyond Jaguar’s control. Unless required by applicable law, Jaguar does not intend to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, long-term occasions, adjustments in cases or otherwise.
Contact: Peter Hodge Jaguar Health, Inc. [email protected]
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
See the accesswire.com edition: https://www.accesswire.com/601540/Jaguar-Health-Inc-Reports-2020-Second-Quarter-Financial-Results